Table 1

Functional measurements before and after bronchodilator administration in the PFT study groups

CharacteristicGroupPre-BD
Median (IQR)
Post-BD
Median (IQR)
Mean delta change (95% CI)
Mean % change (95% CI)
FEV1A1.4 (0.9–2.1)1.5 (2.0–2.2)0.07 (0.069 to 0.074)
5.2 (–1.0 to 12.0)
B2.3 (1.7–2.8)2.4 (1.8–2.9)0.12 (0.118 to 0.129)
5.0 (4.7 to 5.2)
C2.9 (2.4–3.7)3.0 (2.4–3.8)0.1 (0.008 to 0.154)
2.9 (–5.6 to 10.6)
FEV1 % predicted (GLI)A44 (30–59)46 (32–61)1.9 (1.807 to 1.966)
3.4 (3.2 to 3.6)
B71 (56–84)75 (60–88)3.8 (3.6 to 3.9)
5.0 (4.7 to 5.2)
C95 (87–105)99 (91–108)2.5 (1.5 to 3.5)
1.8 (0.4 to 3.3)
FVCA2.9 (2.2–3.7)3.0 (2.3–3.8)0.08 (0.074 to 0.081)
3.0 (–2.3 to 9.0)
B3.4 (2.8–4.1)3.5 (2.9–4.2)0.1 (0.095 to 0.109)
2.5 (2.3 to 2.7)
C3.9 (3.0–4.8)3.9 (3.0–4.9)0.03 (–0.055 to 0.111)
0.1 (–7.1 to 9.0)
FVC % predicted (GLI)A72 (57–87)73 (60–88)1.8 (1.677 to 1.898)
2.1 (1.9 to 2.3)
B82 (71–95)85 (73–98)2.4 (2.2 to 2.6)
2.5 (2.3 to 2.7)
C98 (90–107)99 (91–107)0.6 (–0.4 to 1.6)
−0.3 (–1.8 to 1.1)
FEV1/FVCA0.53 (0.41–0.61)0.54 (0.41–0.63)0.01 (0.009 to 0.010)
1.9 (–2.7 to 6.3)
B0.69 (0.58–0.76)0.71 (0.60–0.78)0.018 (0.017 to 0.019)
2.4 (2.2 to 2.6)
C0.77 (0.72–0.81)0.81 (0.75–0.84)1.6 (1.036 to 2.144)
0.1 (–1.9 to 1.9)
FEV1/FVC % predicted (GLI)A65 (50–75)66 (50–76)0.982 (0.909 to 1.055)
1.0 (0.9 to 1.1)
B88 (75–97)91 (77–99)2.3 (2.2 to 2.5)
2.4 (2.2 to 2.6)
C97 (92–101)100 (95–104)0.1 (–0.2 to 0.4)
1.4 (0.6 to 2.3)
  • A: training and testing combined sets, n=25 017; B: validation set 1 from AVAHCS, n=5854; C: validation set 2 from Cleveland Clinic, n=727.

  • AVAHCS, Atlanta Veteran Affairs Healthcare System in Atlanta, Georgia; BD, bronchodilator; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GLI, Global Lung Initiative; PFT, pulmonary function test.